Investitionsthese
We believe breakthrough science only matters when it reaches people. We back founders solving problems that prevent therapies from reaching patients, including manufacturing bottlenecks, slow clinical development, and inefficient data use.
Investitionsphase
Early-stage to growth-stage
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Breakthrough life sciences companies, including new therapies, scalable manufacturing platforms, and tools for faster clinical development and data analysis
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
€20.865.000 - €92.000.000
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (17)
A
Alan Barge
Venture Partner
C
Carol Lynch
Advisor
C
Christopher Spray
Advisor
C
Colin Freund
Partner
I
Igor Linshits
Founder
I
Iskender Dirik
Partner
J
Jakub Czarnecki
Financial Controller
J
John Campbell
EIR
J
Jonathan Hay
Partner
L
Larry Illg
Advisor
M
Matt Symes
Investor
M
Miguel Forte
Advisor
M
Muz Mansuri
Advisor
O
Oliver Hemmings
Analyst
R
Rosie Barnett
Principal
S
Sarah Shackelton
Advisor
Z
Ziaf Rehman
Associate